Acorda Therapeutics マネジメント

マネジメント基準チェック /24

Acorda Therapeuticsの CEO はRon Cohenで、 Jan1995年に任命され、の在任期間は 29.58年です。の年間総報酬は$ 996.33Kで、 62.7%給与と37.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.6%を直接所有しており、その価値は$ 225.39 。経営陣と取締役会の平均在任期間はそれぞれ6.3年と21.1年です。

主要情報

Ron Cohen

最高経営責任者

US$996.3k

報酬総額

CEO給与比率	62.7%
CEO在任期間	29.6yrs
CEOの所有権	0.6%
経営陣の平均在職期間	6.3yrs
取締役会の平均在任期間	21.1yrs

経営陣の近況

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

May 26

Recent updates

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Feb 21

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Dec 18

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Jun 05

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Oct 17

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Oct 10

CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action

Jun 17

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

May 26

Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Mar 09

CEO報酬分析

Acorda Therapeutics の収益と比較して、Ron Cohen の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$263m
Dec 31 2023	US$996k	US$625k	-US$253m
Sep 30 2023	n/a	n/a	-US$16m
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$58m
Dec 31 2022	US$984k	US$625k	-US$66m
Sep 30 2022	n/a	n/a	-US$106m
Jun 30 2022	n/a	n/a	-US$119m
Mar 31 2022	n/a	n/a	-US$95m
Dec 31 2021	US$2m	US$743k	-US$104m
Sep 30 2021	n/a	n/a	-US$166m
Jun 30 2021	n/a	n/a	-US$132m
Mar 31 2021	n/a	n/a	-US$127m
Dec 31 2020	US$2m	US$796k	-US$100m
Sep 30 2020	n/a	n/a	US$49m
Jun 30 2020	n/a	n/a	-US$222m
Mar 31 2020	n/a	n/a	-US$232m
Dec 31 2019	US$2m	US$796k	-US$273m
Sep 30 2019	n/a	n/a	-US$329m
Jun 30 2019	n/a	n/a	-US$79m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$2m	US$796k	US$34m
Sep 30 2018	n/a	n/a	-US$147m
Jun 30 2018	n/a	n/a	-US$158m
Mar 31 2018	n/a	n/a	-US$213m
Dec 31 2017	US$2m	US$792k	-US$223m

報酬と市場: Ronの総報酬 ($USD 996.33K ) は、 US市場 ($USD 650.80K ) の同規模の企業の平均を上回っています。

報酬と収益: Ronの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Ron Cohen (68 yo)

29.6yrs

在職期間

US$996,328

報酬

Dr. Ron Cohen, M.D., serves as an Independent Director of ZWI Therapeutics, Inc. since January 2024. He has been the Founder of Acorda Therapeutics, Inc. since 1995 and has been its Chief Executive Officer...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ron Cohen	Founder	29.6yrs	US$996.33k	0.60% $ 225.4
Michael Gesser	CFO & Treasurer	2.8yrs	US$611.55k	0% $ 0
Neil Belloff	General Counsel & Corporate Secretary	2.8yrs	US$661.57k	0% $ 0
Denise Duca	Executive Vice President of Human Resources	9.6yrs	データなし	データなし
Kerry Clem	Chief Commercial Officer	2.9yrs	US$592.23k	0.041% $ 15.2
Sofia Ali	Senior VP of Operations & Strategic Planning	no data	データなし	データなし
Susan Way	Senior VP of Drug Development & Regulatory Affairs	no data	データなし	データなし
Wise Young	Special Scientific Advisor	no data	US$10.00k	データなし

6.3yrs

平均在職期間

64yo

平均年齢

経験豊富な経営陣: ACOR.Qの経営陣は経験豊富で経験豊富です（平均在職期間は6.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Ron Cohen	Founder	29.6yrs	US$996.33k	0.60% $ 225.4
John Varian	Independent Director	2.6yrs	US$94.71k	0% $ 0
Carl Cotman	Member of Scientific Advisory Board	no data	データなし	データなし
Sandra Panem	Independent Director	26.6yrs	US$82.65k	0.0019% $ 0.7
Mark Tuszynski	Member of Scientific Advisory Board	no data	データなし	データなし
Melitta Schachner	Member of Scientific Advisory Board	no data	データなし	データなし
Patrick Tresco	Member of Scientific Advisory Board	no data	データなし	データなし
Stephen Waxman	Member of Scientific Advisory Board	no data	データなし	データなし
Mary Bunge	Member of Scientific Advisory Board	no data	データなし	データなし
James Fawcett	Member of Scientific Advisory Board	no data	データなし	データなし
Michael Beattie	Member of Scientific Advisory Board	no data	データなし	データなし
John Kelley	Independent Non-Executive Chairman	15.7yrs	US$140.22k	0% $ 0

21.1yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: ACOR.Qの取締役会は経験豊富で経験豊富です ( 21.1年の平均在任期間)。

Acorda Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Insufficient new directors

Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer

Insufficient new directors

Acorda Therapeutics, Inc. Announces Board Changes

Insufficient new directors

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

Recent updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite Index

Motion for Asset Sale Filed by Acorda Therapeutics, Inc.

Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.

Acorda Therapeutics, Inc. Filed for Bankruptcy

Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

New minor risk - Share price stability

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Third quarter 2023 earnings released: US$7.16 loss per share (vs US$11.41 loss in 3Q 2022)

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA

New minor risk - Shareholder dilution

Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$7.55 loss per share (vs US$55.63 loss in 2Q 2022)

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select Market

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing

First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)

Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)

Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request A Hearing

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027

Acorda Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Acorda inks license deal with Asieris for pre-clinical drug

Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer

Acorda Therapeutics announces resignation of COO

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)

Acorda Therapeutics Receives Deficiency Letter Listing Qualifications Department of Nasdaq Stock Market

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Acorda Therapeutics, Inc. Announces Board Changes

Insufficient new directors

Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)

Acorda Therapeutics: Managing The Transition

Independent Director Barry Greene has left the company

Independent Director Catherine D. Strader has left the company

Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)

Acorda Therapeutics Continues To Maneuver For A Turnaround

CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)

Acorda Therapeutics, Inc. Provides Financial Guidance for the Full Year of 2021

Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

Analysts increase revenue estimates to US$95.7m

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Full year 2020 earnings released: US$12.32 loss per share (vs US$34.47 loss in FY 2019)

Revenue and earnings beat expectations

Acorda Therapeutics Announces Executive Changes

Catalent Pharma Solutions, Inc. completed the acquisition of INBRIJA Manufacturing Operations in Chelsea, Massachusetts from Acorda Therapeutics, Inc. (NasdaqGS:ACOR).

Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent

Price target lowered to US$19.50

Acorda Therapeutics, Inc.(NasdaqGS:ACOR) dropped from Russell 2000 Dynamic Index

New 90-day high: US$6.70

マネジメント基準チェック /24